Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. [electronic resource]
Producer: 20080610Description: 3389-95 p. digitalISSN:- 1538-7445
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents -- therapeutic use
- Benzimidazoles -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Cytogenetic Analysis
- Drug Evaluation, Preclinical
- Gene Amplification -- physiology
- Genomic Instability -- drug effects
- Humans
- Lung Neoplasms -- classification
- Lymphoma -- classification
- Mutation
- Neuroblastoma -- classification
- Protein Kinase Inhibitors -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyridones -- therapeutic use
- Pyrimidines -- therapeutic use
- Receptor Protein-Tyrosine Kinases
- Translocation, Genetic
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.